Senores Pharmaceuticals Limited Q2 FY26 earnings call summary

Earnings call of 6 Nov 2025, summarised by AI from the filing.

Management reiterates at least 50% revenue growth and 100% PAT growth for FY26 over FY25.

Key takeaways

1. FY26 guidance Management reiterates at least 50% revenue growth and 100% PAT growth for FY26 over FY25.
2. Growth driver Regulated market revenue grew 87% YoY in Q2 FY26 on successful launches of own products.
3. Key risk Emerging market growth slow as approvals not converted to commercial orders due to import permits and geopolitical issues.

Original filing on BSE

Senores Pharmaceuticals Limited Q1 FY27 results

As filed: Revenue ₹180 cr (+31% year on year), EBITDA ₹53.8 cr (+58% year on year), PAT ₹30.5 cr (+45% year on year), EBITDA margin 29.8% (+519 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹175 cr (+54% year on year), EBITDA ₹47.5 cr (+150% year on year), PAT ₹36.7 cr (+104% year on year), EBITDA margin 27.1% (+1,000 bps). Score 92 of 100, Above trend. EBITDA margin rose 1000 bps year on year. Other income 37% of PBT. Not enough history for a trend yet: scored on growth alone. Share price after the results: +32.5% in 29 days (Nifty 500: +1.0%).
• Q3 FY26: Revenue ₹175 cr (+69% year on year), EBITDA ₹54.0 cr (+116% year on year), PAT ₹33.6 cr (+110% year on year), EBITDA margin 30.9% (+666 bps). Score 100 of 100, Above trend. EBITDA margin rose 666 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +1.1% in 30 days (Nifty 500: −0.3%).
• Q2 FY26: Revenue ₹162 cr, EBITDA ₹50.0 cr, PAT ₹30.0 cr, EBITDA margin 30.9%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹162 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +1.3% in 29 days (Nifty 500: +0.7%).
• Q1 FY26: Revenue ₹138 cr, EBITDA ₹34.0 cr, PAT ₹21.0 cr, EBITDA margin 24.6%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹138 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +18.9% in 30 days (Nifty 500: −1.9%).
• Q4 FY25: Revenue ₹114 cr, EBITDA ₹19.0 cr, PAT ₹18.0 cr, EBITDA margin 16.7%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹114 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +12.3% in 28 days (Nifty 500: +0.2%).
• Q3 FY25: Revenue ₹103 cr, EBITDA ₹25.0 cr, PAT ₹16.0 cr, EBITDA margin 24.3%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹103 cr). Scored once a year-earlier consolidated quarter exists.

Past price moves after results do not indicate future moves. Not a recommendation.

Senores Pharmaceuticals Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (27 Jul 2026), Results deck (27 Jul 2026)
• Q4 FY26: Earnings call (14 May 2026), Results deck (14 May 2026), Results press release (14 May 2026)
• Q3 FY26: Earnings call (20 Jan 2026), Results deck (20 Jan 2026), Results press release (20 Jan 2026)
• Q2 FY26: Earnings call (6 Nov 2025), Results deck (6 Nov 2025), Results press release (6 Nov 2025)
• Q1 FY26: Earnings call (24 Jul 2025), Results deck (23 Jul 2025), Results press release (23 Jul 2025)
• Q4 FY25: Earnings call (16 May 2025), Results deck (16 May 2025), Results deck (16 May 2025), Results press release (15 May 2025)
• Other events: Strategy deck (15 Dec 2025)